Cargando…
What 20 years of research has taught us about the TP53 p.R337H mutation
The p53 tumor suppressor transcriptionally regulates a myriad of genes involved in cell cycle control, DNA repair, cell survival, and cell metabolism and represents one of the most well‐studied inhibitors of tumorigenesis. Since the discovery of TP53 in 1979, somatic mutations have been shown to be...
Autores principales: | Pinto, Emilia Modolo, Zambetti, Gerard P. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7589304/ https://www.ncbi.nlm.nih.gov/pubmed/32875577 http://dx.doi.org/10.1002/cncr.33143 |
Ejemplares similares
-
Multiple TP53 p.R337H haplotypes and implications for tumor susceptibility
por: Pinto, Emilia M., et al.
Publicado: (2023) -
Occurrence of Neuroblastoma among TP53 p.R337H Carriers
por: Seidinger, Ana Luiza, et al.
Publicado: (2015) -
Environmental Contaminants Modulate Breast Cancer Development and Outcome in TP53 p.R337H Carriers and Noncarriers
por: Gerber, Viviane K. Q., et al.
Publicado: (2022) -
What has vision science taught us about functional MRI?
por: Himmelberg, Marc M., et al.
Publicado: (2022) -
Increased Oxidative Damage in Carriers of the Germline TP53 p.R337H Mutation
por: Macedo, Gabriel S., et al.
Publicado: (2012)